Genmab A/S Sponsored ADR $GMAB Shares Sold by Legacy Wealth Asset Management LLC

Legacy Wealth Asset Management LLC lowered its position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 52.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 22,028 shares of the company’s stock after selling 24,559 shares during the quarter. Legacy Wealth Asset Management LLC’s holdings in Genmab A/S were worth $678,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in GMAB. NewEdge Advisors LLC raised its stake in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. lifted its holdings in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. Community Bank N.A. purchased a new stake in Genmab A/S in the third quarter valued at approximately $47,000. Cromwell Holdings LLC increased its holdings in Genmab A/S by 136.3% in the 3rd quarter. Cromwell Holdings LLC now owns 1,531 shares of the company’s stock worth $47,000 after buying an additional 883 shares during the period. Finally, Osaic Holdings Inc. increased its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. HC Wainwright lifted their price objective on shares of Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Guggenheim cut their price objective on shares of Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, February 23rd. Morgan Stanley began coverage on shares of Genmab A/S in a report on Monday, February 16th. They set an “equal weight” rating and a $34.00 target price for the company. Jefferies Financial Group started coverage on shares of Genmab A/S in a research report on Tuesday, February 17th. They set a “buy” rating and a $41.50 target price for the company. Finally, Wall Street Zen downgraded Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, February 7th. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and a consensus price target of $40.58.

Genmab A/S Trading Up 0.5%

Genmab A/S stock opened at $25.81 on Wednesday. The firm has a market cap of $16.58 billion, a PE ratio of 16.65, a P/E/G ratio of 1.05 and a beta of 0.94. Genmab A/S Sponsored ADR has a 12 month low of $17.24 and a 12 month high of $35.43. The stock’s 50 day simple moving average is $29.87 and its two-hundred day simple moving average is $30.53. The company has a current ratio of 2.02, a quick ratio of 2.01 and a debt-to-equity ratio of 0.86.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Tuesday, February 17th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.06 billion. Analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.